Abstract BW 12C, a substituted benzaldehyde, stabilises haemoglobin in the oxy-conformation and has attracted interest as an anti-sickling agent. The drug causes a left shift in the oxygen saturation curve and may induce tumour anoxia and enhance the effect of cytotoxic drugs. During clinical trials in padents with cancer abnormal bands on haemoglobin electrophoretic strips were observed. This made correct diagnosis of abnormal haemoglobins impossible. Solubility tests for sickling disorders (Itano) also proved unreliable. ( Clin Pathol 1992;45:930) 
BW 12C is a substituted benzaldehyde which causes a dose dependent left shift in the oxygen saturation curve by binding to oxyhaemoglobin.' The drug inhibits sickling by increasing red cell oxyhaemoglobin and reducing the polymerisation of dexoyhaemoglobin. It was initially designed to treat the crises of sickle cell anaemia.2 BW 1 2C induces tumour anoxia and necrosis by reducing peripheral oxygen delivery, and is currently being evaluated in clinical trials for its anti-neoplastic activity. BW 1 2C may synergise with and enhance the cytotoxic effects of chemotherapeutic agents such as mitomycin C which are selectively toxic towards hypoxic or anoxic cells. The abnormal band could be reproduced in vitro by incubating lysates of red cells with therapeutic doses of BW 12C, indicating that BW 12C rather than an active metabolite was responsible for the observed effect (figure). When red cells of patients with structural variants such as sickle cell trait, Hb C trait, and Hb S C disease were studied, additional bands were noted after incubation with BW 12C, making correct interpretation of the results impossible. In homozygous sickle cell anaemia an additional band close to the HbA position was observed.
Routine screening tests (sickle cell preparations and Itano solubility tests) for sickling disorders gave false negative results after BW 12C in heterozygous conditions such as sickle cell trait; in homozygous sickle cell anaemia only low grade positive reactions were recorded. By stabilising sickle cell haemoglobin in the oxy-conformation BW 1 2C protected against the formation of insoluble deoxyhaemoglobin induced by reducing agents (metabisulphite and dithionite) used in screening tests.
Accurate diagnosis of thalassaemic disorders was difficult because the mobility of the haemoglobin A2 band was also altered significantly. Haemoglobin F as measured by the Betke alkali denaturation method was not affected.
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